ReviewAdvances in therapy2024

'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.

Norman Gaylis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.